Biotech Values

[DewDiligence]

Synthetic Biologics, Inc.:

…one of my standard rules of biotech investing - don't invest in companies that change their name.

Do you make an exception when a company changes its name twice? I’m thinking of the case of Pipex Pharmaceuticals --> Adeona --> Synthetic Biologics, Inc.:

http://finance.yahoo.com/news/Adeona-Announces-Proposed-prnews-1391049483.html?x=0

"By overcoming many of the technical obstacles that limited traditional gene medicine approaches, synthetic DNA-based biologics may allow us to optimize the delivery of therapeutic proteins in a safe, controlled and localized fashion never before possible. In turn, this may provide physicians the ability to radically transform the way in which many serious diseases can be treated. I am pleased to be joining the Company, and to be a part of this innovative new effort and area," stated John Monahan , Ph.D., the Company's Senior Vice President of Research & Development.

The Company's ongoing and planned clinical trials of Trimesta™ (estriol) for multiple sclerosis are expected to continue and the Company's planned clinical trial of AEN-100 (modified release zinc) for amyotrophic lateral sclerosis (ALS) is also expected to continue. In addition, the Company intends to seek marketing partners for its marketable zinc-based products reaZin™ and wellZin™.

LOL. One constant through all of the name changes: the company is—and always has been—a hotbed of junk science.

A few Pipex/AEN blasts from the past: #msg-24641786, #msg-24642596, #msg-24675862, #msg-34954043, #msg-46442638.